Related Experiment Video
Updated: Feb 10, 2026
Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
Published on: October 27, 2014
Population Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Children Undergoing Ambulatory Surgery
María-Gabriela Pérez-Guillé1, Alejandra Toledo-López1, Liliana Rivera-Espinosa1
1From the Departamento de Farmacología, Instituto Nacional de Pediatría, México.
Insights
This study analyzed the pharmacokinetics of dexmedetomidine (DEX) in Mexican children undergoing surgery. Results indicate that DEX clearance is lower in this population, suggesting a need for dose adjustments in pediatric anesthesia.
Area of Science:
- Pharmacology
- Pediatric Anesthesiology
- Pharmacokinetics
Background:
- Dexmedetomidine (DEX), an alpha-2 adrenergic agonist, is used for sedation and analgesia.
- Despite its increasing use in pediatric critical care and anesthesia, DEX is not FDA-approved for pediatric use.
- Limited pharmacokinetic data exists for DEX in children.
Purpose of the Study:
- To investigate the pharmacokinetics and pharmacodynamics (PK-PD) of dexmedetomidine (DEX).
- To study DEX PK-PD in Mexican children aged 2-18 years undergoing outpatient surgery.
Main Methods:
- Thirty children (ASA physical status I/II, aged 2-18 years) received a single IV dose of DEX (0.7 μg/kg).
- Plasma DEX concentrations were measured using HPLC and ESI-MS/MS.
- Population PK-PD models were developed using the Monolix program.
Main Results:
- A two-compartment model described DEX concentration-time data.
- Key population PK parameters (CL, V1, V2, Q) were estimated and standardized to a 70 kg body weight.
- The PK-PD model predicted maximal mean arterial blood pressure reduction of 45% (IC50 = 0.501 ng/mL) and heart rate reduction of 28.9% (IC50 = 0.552 ng/mL).
Conclusions:
- The study suggests that dexmedetomidine (DEX) clearance is lower in Mexican children (2-18 years, ASA I/II).
- Dose adjustments for DEX may be necessary in this pediatric population based on reduced clearance.
- Further research into pediatric DEX dosing is warranted.
Background:
Dexmedetomidine (DEX) is an α-2 adrenergic agonist with sedative and analgesic properties. Although not approved for pediatric use by the Food and Drug Administration, DEX is increasingly used in pediatric anesthesia and critical care. However, very limited information is available regarding the pharmacokinetics of DEX in children. The aim of this study was to investigate DEX pharmacokinetics and pharmacodynamics (PK-PD) in Mexican children 2-18 years of age who were undergoing outpatient surgical procedures.
Methods:
Thirty children 2-18 years of age with American Society of Anesthesiologists physical status score of I/II were enrolled in this study. DEX (0.7 μg/kg) was administered as a single-dose intravenous infusion. Venous blood samples were collected, and plasma DEX concentrations were analyzed with a combination of high-performance liquid chromatography and electrospray ionization-tandem mass spectrometry. Population PK-PD models were constructed using the Monolix program.
Results:
A 2-compartment model adequately described the concentration-time relationship. The parameters were standardized for a body weight of 70 kg by using an allometric model. Population parameters estimates were as follows: mean (between-subject variability): clearance (Cl) (L/h × 70 kg) = 20.8 (27%); central volume of distribution (V1) (L × 70 kg) = 21.9 (20%); peripheral volume of distribution (V2) (L × 70 kg) = 81.2 (21%); and intercompartmental clearance (Q) (L/h × 70 kg) = 75.8 (25%). The PK-PD model predicted a maximum mean arterial blood pressure reduction of 45% with an IC50 of 0.501 ng/ml, and a maximum heart rate reduction of 28.9% with an IC50 of 0.552 ng/ml.
Conclusions:
Our results suggest that in Mexican children 2-18 years of age with American Society of Anesthesiologists score of I/II, the DEX dose should be adjusted in accordance with lower DEX clearance.
Related Concept Videos
01:12Analysis of Population Pharmacokinetic Data
01:21Pharmacodynamics: Overview and Principles
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
01:20Measurement of Bioavailability: Pharmacodynamic Methods
02:04Conservation of Small Populations
01:25What is Population Genetics?
00:57Population Growth